Politics · Sri Lanka Bureau
Panel to assess Chinese cancer drug shipment labelling dispute
Sri Lanka's medicines regulator has convened a special medical committee to evaluate whether a large consignment of chemotherapy injections from China can be relabelled and distributed locally. The 160,000 vials of Filgrastim were rejected by authorities over labelling deficiencies.
LSN Sri Lanka ·
The National Medicines Regulatory Authority (NMRA) has established a dedicated medical committee tasked with reviewing the admissibility of a significant shipment of Filgrastim injections sourced from China. The consignment, comprising 160,000 vials intended for cancer patients undergoing chemotherapy, has become the subject of regulatory scrutiny following its rejection by the Medical Supplies Division.
The primary issue preventing clearance of the shipment concerns labelling compliance. The vials arrived without proper labelling, prompting the Medical Supplies Division to decline their acceptance in their current form. The appointment of the specialist committee signals an effort to determine whether local labelling and repackaging could resolve the regulatory impediment.
Filgrastim is a growth factor used to support white blood cell production in patients undergoing cancer treatment. With Sri Lanka facing ongoing challenges in ensuring adequate supplies of essential cancer medications, the outcome of the committee's assessment could have significant implications for patient access to this critical therapeutic agent.
The committee's recommendations are expected to guide NMRA's final determination on whether the consignment meets local regulatory standards for distribution and use within the country's healthcare system.